Related Experiment Video
Updated: Jul 16, 2026
11:13
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
mTOR signaling: implications for cancer and anticancer therapy
E Petroulakis1, Y Mamane, O Le Bacquer
1Department of Biochemistry, McGill Cancer Centre, McGill University, Montreal, QUE, Canada H3G 1Y6.
British Journal of Cancer
|March 30, 2007
Summary
Deregulated protein synthesis drives cancer by affecting the eIF4F complex. Targeting the mTOR pathway with drugs like rapamycin inhibits this process, offering a promising cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Deregulation of protein synthesis is linked to cancer development.
- The eukaryotic initiation factor 4F (eIF4F) complex plays a crucial role in translation initiation and is often overexpressed in various cancers.
- The mechanistic target of rapamycin (mTOR) signaling pathway influences eIF4F activity by phosphorylating eIF4E binding proteins.
Purpose of the Study:
- To investigate the role of the mTOR signaling pathway in regulating eIF4F complex activity and its implications in tumorigenesis.
- To explore the therapeutic potential of targeting the mTOR-eIF4F axis in cancer treatment.
Main Methods:
- Analysis of protein synthesis regulation in cancer models.
- Investigating the effects of mTOR inhibition on eIF4F complex formation and activity.
- Studying the impact of mutations in mTOR regulators on cancer phenotypes.
Main Results:
- mTOR pathway activation leads to increased eIF4F complex formation, promoting enhanced translation initiation and cell growth.
- Rapamycin, an mTOR inhibitor, effectively retards cancer growth.
- Mutations in negative regulators of mTOR result in rapamycin-sensitive cancers.
Conclusions:
- Targeting the mTOR signaling pathway offers a promising therapeutic strategy for inhibiting translation initiation and controlling cancer growth.
- The interplay between mTOR, eIF4F, and protein synthesis is a critical determinant of tumorigenesis.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:54Canonical Wnt Signaling Pathway
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
01:41Non-Canonical Wnt Signaling Pathways
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...